NEW YORK, July 11, 2017 (GLOBE NEWSWIRE) -- According to a new market research report “Global Cancer/Tumor Profiling Market Size, Share, Development, Growth and Demand Forecast to 2023 - Industry Insight by Technology (NGS, QPCR, IHC, ISH, Microarray), by Technique (Genomics, Proteomics, Epigenetics, Metabolomics), by Application (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, and Others),” published by P&S Market Research, the global cancer/tumor profiling market is expected to grow at a CAGR of 19.0%, during 2017-2023.
Browse Detailed Information on Cancer/Tumor Profiling Market: https://www.psmarketresearch.com/market-analysis/cancer-tumor-profiling-market
As per the findings of various researches, next-generation sequencing is the most preferred technology, globally, in the cancer/tumor profiling market. Genomics has been the largest contributor to the global market, in terms of revenue, among the various techniques for cancer/tumor profiling. Genomics involves sequencing and analysis of an organism’s genome, which helps in identifying genes associated with the disease. Based on application, personalized medicine has been the largest segment of the global cancer/tumor profiling market, followed by diagnostics, biomarker discovery, prognostics and others.
Geographically, North America has been the largest market for cancer/tumor profiling, with the U.S. being the largest contributor to the regional market. Increasing government funding for research has been driving the growth of the North American market. In Europe, Germany has been the largest contributor to the cancer/tumor profiling market, followed by the U.K. and France. Asia-Pacific market is expected to grow at the highest CAGR, during 2017-2023, owing to increasing prevalence of cancer and increasing demand for better cancer diagnosis and treatment from emerging economies.
The rapidly increasing burden of cancer has been leading to increase in demand for cancer/tumor profiling, which further compels government organizations and healthcare providers to provide facilities for effective disease diagnosis and treatment. According to WHO, in 2012, approximately 324,000 new cases of lung cancer were diagnosed in North America and the number is likely to reach approximately 541,000 by 2030. Also, as reported by IARC, a total of 645,000 new cancer cases (excluding non-melanoma skin cancer) were reported in 2012, across the globe, and around 456,000 deaths occurred due to the same.
Make Enquiry Before Purchase at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cancer-profiling-market
Some of the key players in the global cancer/tumor profiling market include Illumina, Inc., Caris Life Sciences, Qiagen N.V., Helomics Corporation, Oxford Gene Technology, Neogenomics Laboratories, Inc., HTG Molecular Diagnostics, Inc., Ribomed Biotechnologies, Inc., Genomic Health Inc. and Nanostring Technologies, Inc.
Browse Related Research
Oligonucleotide Synthesis Market
The global oligonucleotide synthesis market is expected to witness a CAGR of 10.5% during the forecast period, to reach $2,744.5 million by 2023. Recent technological advancements in oligonucleotide synthesis and increasing support from government organizations are the key drivers of the global oligonucleotide synthesis market. The market is faced by challenges such as stringent regulations and lack of techniques for large scale synthesis of oligonucleotide. Growing focus on personalized medicine will create enormous revenue generation opportunities for the manufacturers in this market.
https://www.psmarketresearch.com/market-analysis/oligonucleotide-synthesis-market
Microbial Identification Market
The global microbial identification market accounted for $951.8 million revenue in 2015, and it is expected to grow at a CAGR of 6.0% during 2016-2022. The consumables segment accounted for the largest share in the global microbial identification products market in 2015; whereas, among the various end-users, the hospital segment accounted for the highest share in the global market during the same year. The global microbial identification market is witnessing high growth rate, due to the growing incidence of infectious diseases, technological advancement in microbial identification instruments, and increasing healthcare expenditure. Also, the growing food safety concerns are further propelling the growth of the global microbial identifications market.
https://www.psmarketresearch.com/market-analysis/microbial-identification-market
Next-Generation Antibody Therapeutics Market
The global next-generation antibody therapeutics market was worth $1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020. Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others.
https://www.psmarketresearch.com/market-analysis/next-generation-antibody-market
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com